ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

DiCello Levitt LLP Announces Investor Class Action Against Evolv Technolgies Holdings, Inc. (NASDAQ: EVLV, EVLVW) – May 24, 2024, Lead Plaintiff Deadline

SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that purchasers or acquirers of Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. (“Evolv” or the “Company”) (NASDAQ: EVLV, EVLVW) securities between June 28, 2021 and March 13, 2024, inclusive (the “Class Period”), have until May 24, 2024 to seek appointment as lead plaintiff of the Evolv class action lawsuit. The Evolv lawsuit charges the Company and certain senior executive officers with violations of the federal securities laws.

If you purchased Evolv securities and suffered substantial losses, and you wish to serve as lead plaintiff in this lawsuit, you may submit your losses here: https://dicellolevitt.com/securities/evolv-technologies

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Case Allegations:   The Evolv lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) Evolv materially overstated the efficacy of its products; (ii) the lack of effectiveness of Evolv’s products with regard to detecting knives and guns led to an increased risk of undetected weapons entering locations such as schools; and (iii) Evolv deceived the general public, its customers, and its investors regarding the effectiveness of its products.

The Evolv lawsuit also alleges that on November 2, 2022, IPVM released a report entitled “BBC Exposes Evolv with IPVM Research” that described that a “BBC report based on 1,000+ pages of documents obtained by IPVM has exposed security screening manufacturer Evolv for deceptive marketing and colluding with NCS4, a public entity, to hide test results showing failures at weapons screening.” In addition, on the same day, BBC released an article entitled “Manchester Arena’s weapon scanning tech questioned.” The Evolv lawsuit alleges that on this news, the price of Evolv stock fell more than 8% over two trading sessions.

The Evolv lawsuit further alleges that on May 23, 2023, BBC News published an article entitled “AI scanner used in hundreds of US schools misses knives” which stated that “[a] security firm that sells AI weapons scanners to schools is facing fresh questions about its technology after a student was attacked with a knife that the $3.7 [million] system failed to detect.” According to the lawsuit, this news caused the price of Evolv stock fell almost 8%. And the lawsuit describes further declines in response to adverse news and publications on October 12, 2023, and October 25, 2023.

Then, on February 20, 2024, according to the Evolv lawsuit, the Company revealed that it had been notified by U.S. Securities and Exchange Commission that it was initiating an investigation described as a confidential “‘non-public, fact finding inquiry.’” On this news, the price of Evolv stock fell nearly 16%.

And finally, on March 13, 2024, as alleged in the Evolv lawsuit, the BBC released an article entitled “AI weapons scanner backtracks on UK testing claims” which described how “Evolv told BBC News it had altered its claims about UK testing to ‘better reflect the process taken.’” The lawsuit alleges that on this news, the price of Evolv stock again fell.

About DiCello Levitt: At DiCello Levitt, we are dedicated to achieving justice for our clients through class action, business-to-business, public client, whistleblower, personal injury, civil and human rights, and mass tort litigation. Our lawyers are highly respected for their ability to litigate and win cases – whether by trial, settlement, or otherwise – for people who have suffered harm, global corporations that have sustained significant economic losses, and public clients seeking to protect their citizens’ rights and interests. Every day, we put our reputations – and our capital – on the line for our clients.

DiCello Levitt has achieved top recognition as Plaintiffs Firm of the Year and Trial Innovation Firm of the Year by the National Law Journal, in addition to its top-tier Chambers and Benchmark ratings. The New York Law Journal also recently recognized DiCello Levitt as a Distinguished Leader in trial innovation. For more information about the Firm, including recent trial victories and case resolutions, please visit www.dicellolevitt.com.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Media Contact

Christine Schiffner: (703) 862-5202 or cschiffner@dicellolevitt.com 


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.16
-0.51 (-0.22%)
AAPL  277.55
+0.58 (0.21%)
AMD  214.24
+8.11 (3.93%)
BAC  52.99
+0.51 (0.97%)
GOOG  320.28
-3.36 (-1.04%)
META  633.70
-2.52 (-0.40%)
MSFT  485.50
+8.51 (1.78%)
NVDA  180.26
+2.44 (1.37%)
ORCL  204.96
+7.93 (4.02%)
TSLA  426.58
+7.18 (1.71%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.